Caveat: subjective reports are extremely scarce and unreliable. The community pool is single-digit user accounts, dosing is inconsistent, and sourcing reliability is extremely low — meaning reported effects may reflect impurities or unidentified compounds rather than ITPP itself. What follows is summary with very heavy caveats.

• First doses (IV/IP — the routes that have any plausible chance of biological effect): Reported subjective signal is subtle to absent acutely. Some users describe a sensation of "easier breathing" within hours of administration, occasionally with a transient mild headache (consistent with cerebral perfusion changes from altered O2 delivery), but reports are inconsistent and the headache could equally reflect acid-base or polyphosphate-related shifts.
• Days 1-7: If the molecule has actually loaded RBCs, a subset of users report lower perceived exertion at fixed cardio workload — the type of subjective signal you'd predict from rightward curve shift. Reports are not quantified objectively (no power-output, no HR, no lactate measurements in the public anecdotal pool).
• Weeks 2-4: Reported endurance benefit either persists, fades, or never manifested. The degree of attribution to ITPP vs concurrent training adaptation is essentially impossible to isolate from anecdotal reports.
• Side effect patterns reported: transient hypotension, mild dehydration sensation (possibly from polyphosphate osmotic effects), occasional nausea with IV, and rare reports of headache or visual disturbance during initial dosing. No published mortality or serious adverse event data in non-trial use exists in any organized form.
• Oral dosing: Multiple anecdotal reports of users dosing ITPP orally in 100-500 mg quantities. Oral bioavailability of polyphosphates is poor to negligible — these reports are very likely physiologically null and the perceived effects are placebo or other-compound contamination.

Honest framing: ITPP is not a stim, not a feel-it-immediately compound, and the cleanest theoretical phenomenology is "subtly easier cardio" without an obvious mood/cognition signature. Reports of dramatic acute effects are not consistent with the mechanism and are most likely placebo, dosing-artifact, or impurity-driven.

• Tolerance buildup: Unknown for the human ITPP-Hb interaction. Mechanistically: each new RBC cohort would need to be loaded; the loaded-cohort effect persists ~120 days. There is no obvious receptor-level desensitization pathway, but RBC turnover + dosing economics make sustained continuous use mechanistically odd.
• Recommended cycle (if used at all): Cannot be specified — no validated human protocol.
• Reset protocol: RBC turnover (~120 days for full cohort replacement) is the natural reset window if the molecule is dosed once and then stopped.
• Long-term cumulative use: Strongly cautioned against — no data, no signal, no rationale.

Synergistic (theoretical, not validated in humans)

• Iron sufficiency. Ensures RBC mass and Hb concentration are adequate to actually carry the oxygen the modified Hb will offload more efficiently. Iron-deficient state nullifies any ITPP benefit.
• Endurance training. ITPP works on the unloading side of the curve; training increases capillary density, mitochondrial density, and tissue O2 utilization. The two layers are mechanistically complementary if the molecule were ever validated. For users in this archetype: he is already a trained MMA athlete — his peripheral O2 utilization machinery is already substantially developed; marginal benefit of pharmacological right-shift is most uncertain in this exact population.

Avoid stacking with

• EPO / erythropoiesis-stimulating agents. Layered O2-economy modifiers, layered WADA violations, no clinical data.
• HIF-PHIs (roxadustat, daprodustat). Conflicting hypoxia signals + WADA banning.
• Blood transfusion / autologous blood doping. Stacked O2-economy modifiers + multiple WADA M1 violations.
• MOTS-c, SLU-PP-332, other exercise-mimetic research chems. Too many novel signals at once + cumulative WADA exposure + attribution becomes impossible.
• High-dose phosphate supplementation. Additive renal load.

Neutral / safe co-administration

• All V4 daily core supplements (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine/L-tryptophan, D3/K2, beta-alanine, vitamin C)
• Standard sports supplementation (creatine, electrolytes, protein)
• Modafinil, BPC-157, TB-500 — different mechanisms, no documented interaction (but the WADA ban applies to ITPP regardless)

• CYP enzymes: Not metabolized via canonical CYP pathway (it is a polyanion, not lipophilic). Minimal CYP-based drug interaction concern.
• Anticoagulants / antiplatelets: Theoretical interaction with coagulation cascade given polyanion structure. No documented clinical interaction; use caution.
• Phosphate-binders (sevelamer, calcium carbonate): Theoretical concern that phosphate-binders could interfere with the molecule, but ITPP is a structured polyphosphate not a free phosphate ion — clinical relevance unknown.
• Diuretics: Loop diuretics affect phosphate handling; theoretical caution with co-administration.
• Caffeine, alcohol: No documented interaction.
• Other peptides / nootropics in user's stack: No documented interaction with BPC-157, TB-500, modafinil, Cerebrolysin, Semax, etc. — different mechanism, different metabolic pathway.

• No ITPP-specific pharmacogenomic data exists. The molecule has not been administered to humans in any genotyped cohort published in the open literature.
• Indirect candidate gene relevance:
  • HBB (β-globin) variants: Hemoglobin variants (HbS, HbC, HbE, β-thalassemia traits) modify the substrate of ITPP action. Effect of ITPP on variant Hbs is mostly favorable in HbS but uncharacterized in others.
  • 2,3-BPG metabolism (BPGM): Variants affecting baseline 2,3-BPG levels could modify the effective Kd / displacement competition for the ITPP-binding site. No clinical data.
  • Renal phosphate handling (SLC34A1, SLC34A3, FGF23 pathway): Variants affecting renal phosphate transport modify the safety profile of phosphate loading. Relevant for any sustained ITPP dosing.
• Action item: None. ITPP is not in a state where pharmacogenomic optimization is a meaningful consideration; the binary "use / don't use" decision dominates.

Cost math: Even if sourcing were reliable, gram-scale dosing × cumulative protocols = significant material cost (~hundreds to low-thousands of dollars per cycle if vendor pricing follows research-chem norms). Cost is meaningful but not the primary deterrent — the deterrent is the absence of human safety data + WADA ban + sourcing identity reliability problem.

Quality verification on receipt (for the user who overrides SKIP-FOR-NOW — currently NOT recommended):

• Demand vendor-provided NMR + mass spec confirming the molecule is actually myo-inositol trispyrophosphate
• Independent third-party verification (Janoshik or similar) — strongly indicated for any sample, baseline cost ~$80-150 for analytical workup
• Polyphosphate stability check: hydrolysis under storage conditions is a real concern; degraded ITPP is a mixture of inositol phosphate fragments with no oxygen-affinity-modifying activity
• Reconstitution: dissolution in sterile water should yield clear solution; cloudiness or precipitate → discard

Baseline (before any cycle, if user overrides SKIP-FOR-NOW — currently NOT recommended)

• CBC — Hb, hematocrit, RBC count (baseline; ITPP shouldn't change these but baseline is mandatory)
• CMP — including creatinine, eGFR, BUN, calcium, phosphate
• Urinalysis with microscopy — proteinuria and casts as renal-load early indicator
• Blood pressure — multiple readings, ideally home BP cuff
• Resting heart rate, HRV (Whoop / Oura)
• VO2max if accessible — the most direct test of the mechanism's claim
• Lactate threshold if accessible — power output at fixed lactate level
• Cardio benchmark — 5K time, time-to-exhaustion at fixed pace, sport-specific (round capacity at fixed RPE)
• Body composition (DEXA preferred, BIA acceptable)
• Baseline ECG — for any cycle of an O2-economy modifier
• Iron panel — ferritin, transferrin saturation; iron-deficient states nullify any ITPP benefit
• 23andMe pull — HBB variants, BPGM variants, renal phosphate transport variants (information value is mostly hypothetical; not actionable in current state)

During cycle (if used — currently NOT recommended)

• BP daily
• Serum phosphate, creatinine, urinalysis weekly
• Symptom log daily (headache, exertional dyspnea, fatigue, vision changes)
• HR, HRV daily (existing rings/wearables)
• Cardio session subjective RPE log
• Any abnormality → discontinue immediately

Post-cycle (if used — currently NOT recommended)

• Repeat full baseline panel at 2 weeks and 8 weeks post-cessation
• Repeat VO2max + cardio benchmark (with caveat: training adaptation will dominate the signal at 8 weeks)
• Repeat ECG
• Decision rule: any renal abnormality → permanent discontinuation. Any cardiac symptom → permanent discontinuation. Subjective cardio improvement alone is insufficient evidence to continue.